This page shows the latest Afinitor news and features for those working in and with pharma, biotech and healthcare.
In a separate arm of the KEYNOTE-581 trial, the partner companies also evaluated Lenvima plus Novartis’ Afinitor (everolimus) in advanced RCC, with this combination also topping Sutent on PFS and
Rare disease treatments navigate tricky market access route. Novartis’ Afinitor in Tuberous Sclerosis Complex (TSC)-related epilepsy patients and Actelion’s pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag) have gained funding
some big sellers like cancer drug Afinitor and Gilenya for multiple sclerosis in 2019, according to a report on aktiencheck.de.
Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective, ... Latterly Sandostatin has played
Earlier this year NICE performed a similar U-turn on Novartis’ kidney cancer drug Afinitor, following an offer of discount earlier and the provision of new evidence.
The UK's National Institute for Health and Care Excellence (NICE) has reversed its previous ruling on Afinitor and is set to recommend the drug for routine NHS use in kidney ... cancer. The U-turn on NICE's 2011 decision comes as the regulator continues
More from news
Approximately 13 fully matching, plus 52 partially matching documents found.
The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.
Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);
In 2010, we had 13 key product approvals and 16 major filings in pharma, including Gilenya, Lucentis and Afinitor," he points out. ... populations. "In Q2 alone, we had four major approvals and two major filings, including Afinitor, Arcapta Neohaler,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
cancer drug Afinitor.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....